Silence Therapeutics Plc (SLN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Company Overview - Silence Therapeutics has over 20 years of experience in siRNA technology, boasting a strong intellectual property portfolio [3] - The company has undergone a reverse merger with a German firm and has established labs in Berlin and the UK, along with a newly opened office in the U.S., indicating a global presence [3] Technology and Efficacy - The siRNA technology utilized by Silence Therapeutics is noted for its safety, durability, and outstanding efficacy demonstrated in various studies [3] - The company is currently engaged in three clinical programs targeting significant areas such as cardiovascular diseases related to Lp(a) and conditions like polycythemia vera (PV) [3]